Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M

EXAGEN INC.

Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.
AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.
FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).
Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.
Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.